Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy

被引:13
作者
Céfai, D
Schwaninger, R
Balli, M
Brunner, T
Gimmi, CD
机构
[1] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland
[2] Univ Bern, Inst Pathol, CH-3010 Bern, Switzerland
关键词
HER-2/neu; tumor cell lines; immune escape; Fas ligand;
D O I
10.1038/sj.cdd.4400862
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mice transgenic for the rat HER-2/neu oncogene (rNeu-TG) developed spontaneous breast tumors that can escape a rNeu-specific immune response induced by active specific immunotherapy (ASI), The ability of these escape tumors to grow appeared to be due to upregulation of the Fas ligand (Fas-L) molecule. In an effort to develop tools for the better elucidation of the role of Fas-L and other regulatory mechanisms in tumor escape, we established cell lines derived from escape tumors. These tumor cell lines retained MHC class I, rNeu and Fas-L expression in vitro and formed tumors in vaccinated mice, Tumor growth was accompanied by permanent Fas-L expression in vivo, both in vaccinated and control vaccinated mice, indicating that these cells have acquired constitutive Fas-L expression. Moreover, these cells induced target cell apoptosis in vitro, Thus, these cells represent a unique tool to elucidate the importance of Fas-L expressed by tumors that escaped efficient systemic immune responses.
引用
收藏
页码:687 / 695
页数:9
相关论文
共 44 条
[1]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[2]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[3]  
Bennett MW, 1998, J IMMUNOL, V160, P5669
[4]   A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells [J].
Böhm, C ;
Hanski, ML ;
Gratchev, A ;
Mann, B ;
Moyer, MP ;
Riecken, EO ;
Hanski, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 217 (1-2) :71-78
[5]  
Céfaï D, 1999, INT J CANCER, V83, P393, DOI 10.1002/(SICI)1097-0215(19991029)83:3<393::AID-IJC16>3.3.CO
[6]  
2-D
[7]  
Céfai D, 2001, INT J CANCER, V91, P529, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1074>3.0.CO
[8]  
2-O
[9]  
Chappell DB, 1999, CANCER RES, V59, P59
[10]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717